Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.
Oral Presentation: Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat: Results of a Placebo-Controlled, Double-Blind, First-in-Human (FIH) Clinical Trial
Speaker: Stephen Harrison, M.D., Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford and Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, TX